SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial

Abroad (travel likely)RecruitingPHASE2

Conditions

Heart Failure With Preserved Ejection Fraction

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States
Contact: Study coordinator (Cassandra J Demastus) · Cassandra.Demastus@Pennmedicine.upenn.edu

Study leads

Payman Zamani, MD
Principal Investigator
University of Pennsylvania

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)

Heart Failure

Abroad (travel likely)RecruitingPHASE2

Beverly Hills, United States · Lake Forest, United States

Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

Heart Failure

IsraelRecruitingPHASE2

Birmingham, United States · Lakewood, United States

EXercise and Activin Inhibition to Modulate InflammatioN Effects on Heart Failure and Cognition (EXAMINE-HFC)

Heart Failure With Preserved Ejection Fraction

Abroad (travel likely)RecruitingPHASE2

Boston, United States

Coronary Artery Stents in Heart Failure With Preserved Ejection Fraction

Heart Failure With Preserved Ejection Fraction (HFPEF) · Coronary Artery Disease

Abroad (travel likely)RecruitingPHASE2

London, United Kingdom